(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
03 January 2019 (03.01.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/006062 A1

(51) International Patent Classification:
A61K 39/00 (2006.01) *C07K 16/00* (2006.01)
A61K 39/395 (2006.01) *C07K 16/18* (2006.01)
A61P 25/28 (2006.01) *C07K 16/46* (2006.01)

(21) International Application Number:
PCT/US2018/039905

(22) International Filing Date:
28 June 2018 (28.06.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/526,835 29 June 2017 (29.06.2017) US

(71) Applicant: **THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK** [US/US]; 535 West 116th Street, New York, New York 10027 (US).

(72) Inventors: **JONES, Tarran**; 1 Christchurch Crescent, Radlett Hertfordshire WD7 8A9 (GB). **LEVY, Alison**; 8 The Chowns, Harpenden Hertfordshire AL5 2BN (GB). **O'BRIEN, Siobhan**; 10 the ridings, Throley, Bishops Stortford Hertfordshire CM234EH (GB).

(74) Agent: **CUNNINGHAM,, Marina, F.,**; McCormick, Paulding & Huber LLP, 185 Asylum Street, CityPlace II, 18th Floor, Hartford, Connecticut 06103-3410 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CHIMERIC ANTIBODIES FOR TREATMENT OF AMYLOID DEPOSITION DISEASES

Figure 1



(57) Abstract: A chimeric mouse-human antibody for treatment of amyloid deposition diseases, pharmaceutical compositions comprising the antibody, methods and materials for producing the antibody, and methods for treating an amyloid deposition disease using the antibody and the pharmaceutical composition.

WO 2019/006062 A1

[Continued on next page]

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

CHIMERIC ANTIBODIES FOR TREATMENT OF AMYLOID DEPOSITION DISEASES

REFERENCE TO A SEQUENCE LISTING SUBMITTED BY EFS-WEB

[0001] The contents of the ASCII text file of the sequence listing named "8441-0004-1_ST25", which is 15.6 kb in size, was created on June 4, 2018, and electronically submitted via EFS-Web with this application is incorporated herein by reference in its entirety.

CLAIM FOR PRIORITY

[0002] This application claims priority from United States provisional patent application 62/526,835, filed June 29, 2017, which is incorporated herein by reference in its entirety.

GOVERNMENT RIGHTS

[0003] This invention was made with United States government support under Contact 20XS094A, awarded by the Science Applications International Corporation - Frederick. Thus, the United States government may have certain rights to the invention described and claimed herein.

FIELD OF THE INVENTION

[0004] The present invention relates to chimeric mouse-human antibodies useful to treat amyloid deposition diseases, particularly primary (AL) amyloidosis, pharmaceutical compositions comprising such antibodies, methods and materials for preparing such antibodies, and methods of treating amyloid deposition diseases using said antibodies and pharmaceutical compositions.

BACKGROUND OF THE INVENTION

[0005] Native antibodies are usually heterotetrameric glycoproteins of about 150,000 daltons composed of two identical light chains and two identical

heavy chains. Each light chain is linked to a heavy chain by one disulfide bond, while the number of additional disulfide linkages between the heavy chains varies with different antibody isotypes. The simplest isotype is IgG, which comprises just two light chains and two heavy chains, in which the two heavy chains are linked by two disulfide linkages. Each heavy chain has a variable domain (V_H) at one end with a number of adjacent constant domains. Each light chain has a variable domain (V_L) at one end and a constant domain at its other end. Each variable domain of the light and heavy chain in an antibody comprises three segments called complementarity-determining regions ("CDR") or hypervariable regions. Each CDR in a light chain, together with the corresponding CDR in the adjacent heavy chain, form an antigen-binding site of the antibody. Light chains are of two major types, κ and λ, depending on their constant region. Both κ and λ light chains may combine with any of the different heavy chain types.

[0006] Amyloid light-chain amyloidosis (AL amyloidosis), also called primary amyloidosis, is the most common form of systemic amyloidosis in the United States. The term "amyloidosis" refers to a cluster of diseases which share a common feature, i.e, the extracellular deposition of pathologic insoluble fibrillar proteins in organs and tissues (Rodney, et al. – *NEJM*, **25**:898). Amyloidosis is caused by malfunction of a person's antibody-producing cells causing production of abnormal protein fibers which aggregate to form insoluble amyloid deposits in organs and tissues. The type of amyloidosis is determined by the nature of the precursor proteins which form the fibril deposit. In primary amyloidosis (AL), the fibrils comprise fragments of immunoglobulin light chains and in secondary amyloidosis, the fibrils comprise amyloid A protein. Modern classification of amyloidosis is based on the nature of the precursor plasma proteins which form the fibril deposit.

[0007] The precursor plasma proteins are diverse and unrelated. Nevertheless, all precursor deposits produce amyloid deposits which share a common typical **β**-pleated-sheet configuration, which is responsible for the typical staining properties of the fibrillar deposits. The final stage in the development of

amyloidosis is the deposit of amyloid fibrils in the organs of the sufferer. Amyloidosis mortality is high, with current five-year survival rates of about 28%.

[0008] To date, the treatment of AL has been directed towards reducing the synthesis of amyloidogenic precursor light chains by attacking the malfunctioning cells through conventional or high dose cytotoxic chemotherapy. This treatment suffers from two disadvantages. First, the fibrillar deposits are often asymptomatic until after significant deposition has taken place. Therefore, treatment is unlikely to be undertaken before significant deposits have already occurred. Second, since this treatment is at best effective only to stop the production of precursor abnormal protein but not to remove the existing deposits, prognosis for AL patients remains exceedingly poor due to persistence (or progression) of the pathologic deposits (Solomon, et al. – *Int. J. Exp. Clin. Invest.* **2**:269)

[0009] Recent animal studies have shown that the administration of the murine 11-1F4 antibody and other murine anti-human light chain specific antibodies directed against an epitope common to the **β**-pleated-sheet structure present on AL fibrils results in complete degradation of the human AL**κ** and ALλ amyloid deposits. Some of these murine antibodies are described in United States patent 8,105,594, which is incorporated herein by reference in its entirety.

[0010] Murine antibodies are generally unsuitable for administration to other animal species (such humans) because the receiving species will recognize the murine antibody as antigenic and will produce antibodies against it. The antigenicity of an antibody from one species when injected into another species is normally caused by a portion of a constant domain. Such an antigenic response will impede or prevent the desired therapeutic effect of the murine antibody. In humans, this antigenic response is called human anti-mouse antibody (HAMA). The antibodies described in the ‘594 patent have the potential to be highly immunogenic in humans via the human anti-mouse antibody (HAMA) response. Since the HAMA response usually results in the

rapid clearance of a mouse antibody from the human recipient, HAMA would severely limit any potential human therapeutic benefit a murine antibody could have. Therefore, these murine antibodies are unsuitable for administration to a patient to halt or reverse the deposition of amyloid fibrils in a patient and a need exists for an antibody treatment for amyloid deposition diseases that has low immunogenicity in humans.

SUMMARY OF THE INVENTION

[0011] One embodiment of the invention is chimeric mouse-human antibodies useful for treatment of amyloid deposition diseases, particularly primary (AL) amyloidosis.

[0012] Another embodiment of the invention is a pharmaceutical composition comprising the chimeric antibody and a pharmaceutically acceptable carrier.

[0013] Another embodiment of the invention is methods and materials for producing such antibodies, including polynucleotide sequences and vector constructs.

[0014] Another embodiment of the invention is methods for treating or ameliorating the symptoms of amyloid deposition diseases, such as primary (AL) amyloidosis, in a human in need of such treatment by administering to a human patient in need of such treatment or amelioration an effective amount of at least one of such antibodies effective to treat or ameliorate the symptoms of said amyloid deposition disease, together with a pharmaceutically acceptable carrier.

[0015] Another embodiment of the invention is a method of detection of an amyloid deposition disease in a patient suspected of having such disease by administering a labeled antibody of the invention and detecting the presence of the label in the patient. The label may be a radiolabel, such as

^{124}I, but other sorts of labels can be readily envisioned by one of skill in the art. Included in this embodiment is the labeled antibody itself.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 outlines the strategy used to clone the murine V_H and V_K genes from a hybridoma cell line.

[0017] Figure 2 is a listing of DNA and amino acid sequences of the murine 11-1F4 antibody V_H region gene, SEQ ID NO: 39 and NO: 35, respectively.

[0018] Figure 3 is a listing of DNA and amino acid sequences of the murine 11-1F4 antibody V_K region gene, SEQ ID NO: 40 and NO: 36, respectively.

[0019] Figure 4 is a map of the immunoglobulin kappa light chain expression vector pKN100. It consists of a pSV2 vector fragment, which has the SV40 early and crippled SV40 late promoter, the SV40 origin and the Co1E1 origin. It also has the ampicillin resistance and neo genes. The crippled SV40 late promoter drives the neo genes. It also has the HCMVi promoter, a multiple cloning site (containing the *Bam*HI and *Hind*III restriction sites) for the insertion of an immunoglobulin variable region gene, and cDNA for the human kappa constant region gene terminated by a spaC2 termination signal sequence ("Arnie"), which is in the same orientation as the kappa light chain expression cassette.

[0020] Figure 5 is a map of the immunoglobulin gamma 1 heavy chain expression vector pG1D200. It consists of a pSV2dhfr vector fragment, which has the SV40 early and crippled SV40 late promoter, the SV40 origin, and the Co1E1 origin. It also has the ampicillin resistance and *dhfr* genes. The crippled SV40 late promoter drives the *dhfr* gene. Consequently, expression is poor, allowing for the selection of multigene/high expression level clones using comparatively low levels of methotrexate. It also has the HCMVi promoter

fragment, a multiple cloning site, cDNA for a human gamma 1 constant region gene (intron minus) which is followed by a spaC2 termination signal sequence ("Amie").

[0021] Figure 6 is a listing of the DNA and amino acid sequences of the modified murine 11-1F4 antibody V_K region gene (SEQ ID NO: 42 and NO: 47, respectively) and the sequences of the oligonucleotide primers used to modify the V_K gene (SEQ ID NO: 41 and NO: 43, respectively), as well as the DNA sequence with leader (SEQ ID NO: 37).

[0022] Figure 7 is a listing of the DNA and amino acid sequences of the modified murine 11-1F4 antibody V_H region gene (SEQ ID NO: 45 and NO: 48, respectively) and the sequences of the oligonucleotide primers used to modify the V_H gene (SEQ ID NO: 44 and NO: 46, respectively), as well as the DNA sequence with leader (SEQ ID NO: 38).

[0023] Figure 8 is a graphical representation of the result of the amyloid fibril binding ELISA assay. The cos cell supernatants containing chimeric 11-1F4 antibody were tested separately on the same ELISA plate along with purified murine 11-1F4 antibody. The absorbance was read at OD405.

New sv = pG1KD200-11-1F4.
New co-transfection = 11-1F4VHpG1D200 plus 11-1F4VK.pKN100.

DETAILED DESCRIPTION OF THE INVENTION

[0024] In accordance with the present invention, chimeric mouse-human antibodies are provided that are useful for administration to humans suffering from amyloid deposition diseases to treat or ameliorate the symptoms of the disease. The chimeric antibodies of the invention bind to amyloid deposits and activate the patient's immune system to clear the bound materials while producing little or no HAMA reaction. The invention also provides pharmaceutical compositions comprising at least one of said chimeric antibodies and a pharmaceutically acceptable carrier, methods and materials

for producing these antibodies, and methods of treating or ameliorating the symptoms of a patient suffering from amyloidosis by administering to the patent an amount of the chimeric antibody effective to remove at least some of the amyloid deposits from the patient's organs and thus to treat or ameliorate the symptoms of the amyloidosis.

[0025] In the present invention, at least one chimeric antibody is administered to a human patient suffering from amyloidosis to promote the degradation and removal of at least some of the amyloid fibrils which have become deposited in the organs of the patient. A therapeutically effective amount of the antibody is administered together with a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers are well-known in the art. A typical route of administration is parenterally (e.g., intravenously), as is well understood by those skilled in the medical arts. Other routes of administration are of course possible. Administration may be by single or multiple doses. The amount of antibody administered and the frequency of dosing may be optimized by the physician for the particular patient.

[0026] The therapeutically effective dose of antibody administered to the patient (whether administered in a single does or multiple doses) should be sufficient to reduce the amount of deposited amyloid fibrils in the patient. Such therapeutically effective amount may be determined by evaluating the symptomatic changes in the patient or by evaluating the change in the amount of deposited amyloid fibrils (e.g., by radioimmune detection of deposited amyloid deposits using ^{124}I tagged antibody). Thus, labeled antibody of the invention may be used to detect the presence of amyloid deposition disease on a patient suspected of having the disease as well as to determine the effectiveness of treatment.

[0027] To produce the chimeric antibodies of the invention, the murine 11-1F4 monoclonal antibody heavy and kappa light chain variable region genes described in United States patent 8,105,594 were PCR modified to facilitate the

expression of the chimeric 11-1F4 antibody in mammalian cells. A detailed sequence analysis of the modified variable region genes was performed. The modified variable region genes were cloned into the appropriate mammalian expression vectors, creating the constructs 11-1F4VHpG1D200 and 11-1F4VK.pKN100. A single supervector construct, pG1KD200-11-1F4, was made from the 11-1F4VHpG1D200 and 11-IF4VK.pKN100 constructs by EcoRI restriction enzyme digest and ligation. Finally, the chimeric 11-1F4 antibody was transiently expressed in COS cells by both cotransfection and single supervector transfection. While COS cells were chosen for the co-transfection or transfection as a matter of convenience, those of skill in the art would recognize that other mammalian cell lines could be used. The characterization of the binding capacity of the chimeric 11-1F4 antibody for amyloid fibrils was determined by direct binding ELISA. Unexpectedly and beneficially, the chimeric 11-1F4 antibody bound to amyloid fibrils with higher affinity than the murine 11-1F4 antibody.

[0028] The antibody of the invention comprises a chimeric mouse-human monoclonal antibody comprising the V_K region of SEQ ID NO: 47 and the V_H region of SEQ ID NO: 48. This antibody binds to an epitope expressed by the β-pleated sheet configuration of amyloid fibrils. Moreover, surprisingly the antibody binds to this epitope with higher affinity than the 11-1F4 mouse antibody from which it was derived, which comprises the V_K region of SEQ ID NO: 36 and the V_H region of SEQ ID NO: 35. The invention includes methods of treating an amyloid deposition disease in a human patient in need of such treatment which comprises administering to the patient the above antibody in a pharmaceutically-acceptable carrier. The amount of antibody administered should be effective to reduce the amount of amyloid fibrils deposited in the tissues of the patient. The antibody composition may be administered by any conventional route of administration, but parenteral administration (such as intravenous) is preferred. Pharmaceutically-acceptable carriers are well-known in the art and a suitable one can be selected by one of skill in the medical field. The amyloid deposition disease is preferably primary (AL) amyloidosis.

[0029] The invention also includes methods and materials for making the

subject antibody. Materials useful to make the subject antibody include vector constructs selected from the group consisting of 11-1F4VK.pKN100 and 11-F4VH.pG1D200, shown in Figures 5 and 6, respectively, and the superconstruct pG.1KD20011-1F4 made from the two above vector constructs. Other useful materials include the modified murine 11-1F4 antibody V_K region gene (SEQ ID NO: 42) and the modified 11-1F4 antibody V_H region gene (SEQ ID NO: 45), as well as the respective primers SEQ ID NO: 41, 43, 44, and 46. The subject antibody may be made by co-transfection of the vector constructs 11-1F4VK.pKN100 and 11-F4VH.pG1D200 or the superconstruct pG.1KD20011-1F4 in a suitable mammalian host cell, such as COS (Chinese hamster ovary) cells.

Abbreviations

[0030] Dulbecco's Modified Eagles Medium (DMEM), Fetal Bovine Serum (FBS), ribonucleic acid (RNA); messenger RNA (mRNA); deoxyribonucleic acid (DNA); copy DNA (cDNA); polymerase chain reaction (PCR); minute (min); second (sec); Tris-borate buffer (TBE).

[0031] Amino acids are represented by the IUPAC abbreviations, as follows: Alanine (Ala A), Arginine (Arg; R), Asparagine (Asn; N), Aspartic acid (Asp; D), Cysteine (Cys; C), Glutamine (Gln; Q), Glutamic acid (Glu; E), Glycine (Gly; G), Histidine (His; H), Isoleucine (Ile; I), Leucine (Leu; L), Lysine (Lys; K), Methionine (Met; M), Phenylalanine (Phe; F), Proline (Pro; P), Serine (Ser; S), Threonine (Thr; T), Tryptophan (Trp; W), Tyrosine (Tyr; Y), Valine (Val; V). Similarly for nucleotides: Adenine (a), Cytosine (c), Guanine (g), Thymine (t), Uracil (u) ,Adenine or Guanine (r), Cytosine or Thymine (y), Guanine or Cytosine (s), Adenine or Thymine (w), Guanine or Thymine (k), Adenine or Cytosine (m), Cytosine or Guanine or Thymine (b), Adenine or Guanine or Thymine (d), Adenine or Cytosine or Thymine (h), Adenine or Cytosine or Guanine (v), and any base (n).

EXAMPLE 1

PCR Cloning and DNA Sequencing of the mouse 11-1F4 Antibody

[0032] The murine 11-1F4 monoclonal antibody heavy and light chain variable region genes were PCR cloned and a detailed sequence analysis of all variable region genes isolated (both pseudo and functional) was performed. Detailed DNA and amino acid sequences of the murine 11-1F4 heavy and light chain variable region genes were obtained.

Materials

[0033] Media components and all other tissue culture materials were obtained from Life Technologies (UK). The RNA solution kit was obtained from Stratagene (USA), while the first strand cDNA synthesis kit was purchased from Pharmacia (UK). All the constituents and equipment for the RCR-reaction, including AmpliTaq® DNA polymerase, were purchased from Perkin Elmer (USA). The TOPO TA Cloning ® kit was obtained from Invitrogen (USA). Agarose (UltraPure™) was obtained from Life Technologies (UK). The ABI PRISM® Big Dye™ terminator cycle sequencing ready reaction kit pre-mixed cycle sequencing kit and the ABI PRISM® 310 sequencing machine were both purchased from PE Applied Biosystems (USA). All other molecular biological products were obtained from New England Biolabs (USA) and Promega (USA).

Methods

[0034] The strategy used to PCR clone the murine V_H and V_K genes from the hybridoma cell lines producing the murine monoclonal antibody 11-1F4 is outlined in Figure 1.

[0035] Two clones (B2C4 and B2D6) of the SP2/0 hybridoma cell line producing the α-human light chain monoclonal antibody 11-1F4, were kindly provided by Alan Solomon, MD (University of Tennessee Medical Center at Knoxville, TN). The hybridoma cell line is available from the American Type Culture Collection (ATCC access PTA-105). The cell lines were cultured using DMEM media supplemented with 20% (v/v) FBS, penicillin/streptomycin and L-Glutamine. Cells were cultured until a total viable cell count of 10^8 cells was reached.

[0036] The cells were harvested separately from each clone as follows. The mouse hybridoma cell line was grown in suspension in an appropriate culture medium and in sufficient quantities to provide a total viable cell count of about 10^8 cells. The culture supernatant was harvested and the hybridoma cells pelleted in a bench top centrifuge (250 g, 5 min). The cells were gently re-suspended in 20 ml PBS and a I00 µl aliquot was taken for a viable cell count. The cells in the aliquot were pelleted once more and 200 µl of PBS and 200 µl of trypan blue were added to the 100 µl of cells and mixed gently. Ten µl of this mixture was pipetted into a disposable cell-counting slide and the number of white cells in 9 small squares was counted under a microscope. Blue cells (i.e. dead cells) were not counted. The count process was repeated, the results averaged, and the average results multiplied by 9×10^5 to obtain a viable cell count for the cells in 20ml PBS. Once sufficient cells had been harvested, they were re-suspended in I0 ml of Solution D for RNA isolation (see below, Stratagene RNA Isolation Kit).

[0037] Total RNA was then isolated separately from the cells of each clone using a Stratagene RNA isolation kit, according to the manufacturer's instructions. One ml of 2 M sodium acetate (pH 4.0) was added to the sample and the contents of the tube were thoroughly mixed by repeatedly inverting the tube. To the tube was added 10.0 ml of phenol (pH 5.3-5.7) and the contents again mixed thoroughly by inversion. To the mixture was added 2.0 ml of chloroform-isoamyl alcohol mixture, the tube was capped and vigorously shaken for 10 seconds, and the tube was incubated in ice for 15 minutes. The sample was transferred to a 50-ml thick-walled, round-bottom centrifuge tube that had been pre-chilled on ice and the tube was spun in a centrifuge at 10,000 x g for 20 minutes at 4°C. Two phases were visible in the tube after centrifugation. The upper, aqueous phase contained the RNA, while the lower phenol phase and interphase contained DNA and proteins. The RNA-containing upper, aqueous phase was transferred to a fresh centrifuge tube and the lower phenol phase was discarded. An equal volume of isopropanol was added to the aqueous phase and the contents mixed by inversion, following which the tube was incubated for

1 hour at -20°C to precipitate the RNA. The tube was spun in a centrifuge at 10,000 x g for 20 minutes at 4°C. After centrifugation, the pellet at the bottom of the tube, which contains the RNA, was removed and the supernatant discarded. The pellet was dissolved in 3.0 ml of solution D, 3.0 ml of isopropanol was added to the tube and the contents mixed well. After incubating the tube for 1 hour at -20°C, it was again spun in a centrifuge at 10,000 x g for 10 minutes at 4°C and the supernatant removed from the tube and discarded. (Note: Up to this point. the RNA had been protected from ribonucleases by the presence of guanidine isothiocyanate but was now no longer protected.) The pellet was washed with 75% (v/v) ethanol (DEPC-treated water (25%)) and the pellet was dried under vacuum for 2-3 minutes. The RNA pellet is re-suspended in 0.5-2 ml of DEPC-treated water.

[0038] Following the manufacturer's instructions, an Amersham Pharmacia Biotech first strand cDNA synthesis kit was employed to produce a single-stranded DNA copy of the 11-1F4 hybridoma mRNA using the *Not* I-d(T)^{18} primer supplied with the kit. One reaction was performed for each of the two RNA samples isolated, as follows. The components used were: Bulk first strand cDNA reaction mix, Cloned FPLCpure™ Murine Reverse Transcriptase, RNAguard™, BSA, dATP, dCTP, dGTP, and dTTP, 200 mM DIT aqueous solution, *Not* I-d(T)^{18} primer: 5' -d[AACTGGAAGAATTCGCGGCCGCAGGAA$_{18}$]-3', and DEPC treated water.

[0039] Approximately 5 µg of total RNA in 20 µl DEPC water was heated to 65 'C for I0 min and then chilled on ice. The bulk first strand cDNA reaction mix was pipetted gently to obtain a uniform suspension and the reaction set up in a 0.5 ml microcentrifuge tube as below. 20 µl denatured RNA solution, 11 µl Bulk first strand cDNA reaction mix, 1 µl Not I-d(T)^{18} primer, and 1 ul DTT solution for 33 µl total volume. The reactants were mixed gently by pipetting and incubated 37^{o}C for 1 hour.

[0040] The murine heavy and kappa light chain variable region genes (V_H genes and V_K genes, respectively) were then PCR amplified from the ssDNA

template using the method described by Jones and Bendig (*Bio/Technology* **9**:88).

[0041] Separate PCR reactions were prepared for each of the degenerate leader sequence specific primers (MHVI - MHV12 for V_H and MKVI – MKV11 for V_K) with the appropriate constant region primer (an equimolar mix of MHCI - MHC3 for V_H and MKC for V_K). Tables I & 2 detail the primers used to amplify the V_H and V_K region genes, respectively. In total, 12 heavy chain reactions and 11 kappa light chain reactions were performed. AmpliTaq® DNA polymerase was used to amplify the template cDNA in all cases, as follows.

[0042] The completed cDNA first strand synthesis reaction was heated at 90° C for 5 minutes to denature the RNA-cDNA duplex and inactivate the reverse transcriptase and chilled on ice. Eleven GeneAmp™ PCR reaction tubes were labeled MKV1-11. For each tube a 100 µl reaction mixture was prepared, each reaction mixture containing 69.3 µl of sterile water, 10 µl of 10 X PCR buffer II, 6 µl of 25 mM $MgCl_2$, 2 µl each of the 10 mM stock solutions of dNTPs, 2.5 µl of 10 mM MKC primer, 2.5 µl of one of the 10 mM MKV primers and 1 µl of RNA-cDNA template mix. To each of the tubes was then added 0.7 µl of AmpliTaq® DNA polymerase and the completed reaction mix overlaid with 50 µl of mineral oil.

[0043] A similar series of reaction mixes was prepared as described above to PCR-clone the mouse heavy chain variable region gene. However, this time twelve reaction tubes were labeled and one of the twelve MHV primers and the appropriate MHC primer were added to each. That is, to PCR-amplify the variable domain gene of a mouse γ1 heavy chain, for example, the MHC G1 primer was used.

[0044] The reaction tubes were loaded into a DNA thermal cycler and cycled (after an initial melt at 94° C for 1.5 min) at 94° C for 1min, 50 °C for I min and 72 °C for 1 min over 25 cycles. The last cycle was followed by a final extension step at 72 °C for 10 min before cooling to 4 °C. Except for between the annealing (50 °C) and extension (72 °C) steps when an extended ramp time of

2.5 min was used, a 30 sec ramp time was used between each step of the cycle. A 10 µl aliquot from each PCR reaction was run on a 1% (w/v) agarose /1 X TBE buffer gel containing 0.5 µg/ml ethidium bromide to determine which of the leader primers produced a PCR-product. Positive PCR-clones were about 420-500 bp in size.

[0045] The above PCR-amplification process was repeated twice more and those PCR-reactions that appeared to amplify full-length variable domain gene were selected. A 6 µl aliquot of each potential PCR-product was directly cloned into the pCR™II vector provided by the TA Cloning® kit, as described in the manufacturers instructions. Aliquots of 10.0% (v/v), 1.0% (v/v) and 0.1% (v/v) aliquots of the transformed E.coli cells were pipetted onto individual 90 mm diameter LB agar plates containing 50 µg/ml ampicillin, overlaid with 25 µl of the X-Gal stock solution and 40 µl of IPTG stock solution, and incubated overnight at 37 °C. Positive colonies were identified by PCR-screening.

Table 1. PCR primers for cloning mouse kappa light chain variable region genes

Name	Sequence (5'->3')	SEQ ID
MICV1 (30mer)	ATGAAGATTGCCTGTTAGGCTGTTGGTGCTG	1
MKV2 (30mer)	ATGGAGWCAGACACACTCCTGYTATGGGTG	2
MKV3 (30mer)	ATGAGTGTGCTCACTCAGGTCCTGGSGTTG	3
MKV4 (33mer)	ATGAGGRCCCCTGCTCAGWTTYTTGGMWTCTTG	4
MKV5 (30mer)	ATGGATTTWCAGGTGCAGATTWTCAGCTTC	5
MKV6 (27mer)	ATGAGGTKCYYTGYTSAYCTYCTCTGRGG	6
MKV7 (31mer)	ATGGGCWTCAAAGATGGAGTCACAKWYYCWGG	7
MKV8 (25mer)	ATGTGGGGAYCTKTTTYCMMTTTTTCAATG	8
MKV9 (25mer)	ATGGTRTCCWCASCTCAGTTCCTTG	9
MKV10 (27mer)	ATGTATATATGTTTGTTGTCTATTTCT	10
MKV11 (28mer)	ATGGAAGCCCCAGCTCAGCTTCTCTTCC	11
MKC (20mer)	ACTGGATGGTGGGAAGATGG	12

Table 2. PCR primers for cloning mouse heavy chain variable region genes

Name	Sequence (5'->3')	SEQ ID
MHVI (27mer)	ATGAAATGCAGCTGGGGCATSTTCTTC	13
MHV2 (26mer)	ATGGGATGGAGCTRTATCATSYTCTT	14
MHV3 (27mer)	ATGAAGWTGTGGTTAAACTGGGTTTTT	15
MHV4 (25mer)	ATGRACTTTGGGYTCAGCTTGRTTT	16
MHV5 (30mer)	ATGGGACTCCAGGCTTCAATTTAGTTTTCCTT	17
MHV6 (27mer)	ATGGCTTGTCYTTRGSGCTRCTCTTCTGC	18
MHV7 (26mer)	ATGGRATGGAGCKGGRGTCTTTMTCTT	19
MHV8 (23mer)	ATGAGAGTGCTGATTCTTTTGTG	20
MHV9 (30mer)	ATGGMTTGGGTGTGGAMCTTGCTTATTCCTG	21
MHV10 (27mer)	ATGGGCAGACTTACCATTCTCATTCCTG	22
MHV11 (28mer)	ATGGATTTTGGGCTGATTTTTTTTATTG	23
MHV12 (27mer)	ATGATGGTGTTAAGTCTTCTGTACCTG	24
MHCG1 (21mer)	CAGTGGATAGACAGATGGGGG	25
MHCG2a (21mer)	CAGTGGATAGACCGATGGGGG	26
MHCG2b (21mer)	CAGTGGATGAGCTGATGGGGG	27
MHCG3 (21mer)	CAAGGGATAGACAGATGGGGC	28

[0046] Five µl aliquots from each PCR reaction were run on a 1% agarose/TBE (pH 8.8) gel to determine which had produced a PCR product of the correct size (ca. 450 bp). Those putative positive PCR products so identified were directly cloned into the pCR2.1 vector provided by the TA Cloning® kit and transformed into TOP10 competent cells as described in the manufacturer's protocol. Colonies containing the plasmid with a correctly sized insert were identified by PCR-screening the colonies using the 1212 and 1233 oligonucleotide primers (Table 3) according to the method of Güssow and Clackson (*Nucleic Acids Res.* **17**:4000). Those putative positive clones so identified were double-stranded plasmid DNA sequenced using the ABI PRISM 310 Genetic Analyzer and the ABI PRISM BigDye™ terminator. Three positive

clones each of the V_H and V_K genes from the B2C4 hybridoma cell line clone were sequenced, as were four positive clones of the V_K gene and six of the V_H gene from the B2D6 hybridoma cell line clone.

Table 3. Primers for PCR screening and sequencing transformed colonies.

Name	Sequence (5' -> 3')	SEQ ID
1212 (17mer)	GTTTTCCCAGTCACGAC	29
1233 (21mer)	AGCGGATAATTTCACACAGGA	30

[0047] The results of the 12 PCR reactions performed for each hybridoma clone (B2C4 and BCD6) to amplify the murine 11-1F4 heavy chain variable region gene are presented in Table 4(a).

[0048] The degenerate leader sequence primer MHV7, in combination with a mix of the MHCGI-3 constant region primers (Table 1), yielded a PCR product of about 600 bp from template cDNAs derived from both the B2C4 and B2D6 hybridoma cell lines. Since this band was larger than the expected size for an average V_H gene (450 bp), it was not investigated further. Conversely, the degenerate leader sequence primer MHV6, in combination with a mix of the MHCGI-3 constant region primers (Table 1), yielded a PCR product of the expected size (450 bp) for a V_H gene from template cDNA derived from both the B2C4 and B2D6 hybridoma cell lines.

Table 4. Results of the PCR amplifications performed to clone the murine 11-1F4 monoclonal antibody variable region heavy (a) and light (b) chain genes from the SP2/0 hybridoma cell lines B2C4 and B2D6. Column three contains a record of the actual PCR results. Where a band was observed for a particular combination of primers its size in base pairs (bp) was recorded in the appropriate space.

(a)

C_H Region Primer	Leader Primer	Approximate Band Size (bp)	
		B2C4	B2D6
MHCG1-3 (mix)	MHV1		
"	MHV2		
"	MHV3		
"	MHV4		
"	MHV5		
"	MHV6	450	450
"	MHV7	600	600
"	MHV8		
"	MHV9		
"	MHV10		
"	MHV11		
"	MHV12		

(b)

C_K Region Primer	Leader Primer	Approximate Band Size (bp)	
		B2C4	B2D6
MKC	MKV1	450	450
"	MKV2	<450	<450
"	MKV3		
"	MKV4		
"	MKV5		
"	MKV6	200	
"	MKV7		
"	MKV8		
"	MKV9		
"	MKV10		
"	MKV11		

[0049] Sequence analysis of three clones from the B2C4 derived PCR product and five clones from the B2D6 derived PCR product revealed a single heavy chain variable region sequence (Figure 2).

[0050] The cloning strategy used (amplification of the entire variable region gene by using primers which flank this region, i.e. leader sequence and constant region sequence specific primers) allowed the complete FR1 sequence to be identified. All eight clones sequenced had identical sequence in this region (Figure 2).

[0051] The results of the 11 PCR reactions performed for each hybridoma clone (B2C4 and BCD6) to amplify the murine 11-1F4 kappa light chain variable region gene are presented in Table 4(b).

[0052] The degenerate leader sequence primer MKV6 in combination with the MKC constant region primer (Table 2), produced a PCR product of about 200 bp from template cDNA derived from the B2C4 hybridoma cell line only. Since this band was much smaller than the expected size for a V_K gene (450 bp), it was not investigated further.

[0053] The degenerate leader sequence primer MKV2, in combination with the MKC constant region primer (Table 2), produced a PCR product which was smaller than the expected 450 bp band (when viewed on an agarose gel) from template cDNA derived from both the B2C4 and B2D6 hybridoma cell lines. In addition, previous V_K cloning had found that the MKV2 primer amplified a well known kappa light chain pseudogene. Therefore, sequence analysis of one clone of each PCR product was performed in order to confirm that this product was a pseudogene and not the murine 11-1F4 V_K gene. This sequence analysis revealed that this PCR clone was indeed the pseudogene.

[0054] Finally, the degenerate leader sequence primer MKV1, in combination with the MKC constant region primer (Table 1), produced a PCR product of about the expected size (450 bp) for a V_K gene, from template cDNA derived from both the B2C4 and B2D6 hybridoma cell lines.

[0055] Sequence analysis of three clones of the B2C4 derived PCR product and four clones of the B2D6 derived PCR product revealed a single kappa light chain variable region sequence which could not be identified as a pseudogene.

[0056] Thus, the 11-1F4 heavy chain variable region gene was cloned (using constant region specific and leader sequence specific primers) from the hybridoma mRNA and sequenced.

[0057] When translated, the sequence gave a TVSS peptide sequence. Analysis of 122 rearranged human V_H genes, recorded in the Kabat database (Kabat *et al. - Sequences of Proteins of Immunological Interest*), revealed that 84% of these sequences had a TVSS peptide sequence. It was therefore concluded that the V_H gene isolated was the correct 11-1F4 gene sequence.

[0058] The murine 11-1F4 variable region kappa light chain gene was also successfully cloned and sequenced, as was a non-functional V_K pseudogene gene. This pseudogene was first identified by Carroll et al (*Molecular Immunology* (1988) **25**:991). The sequence arises from an aberrent mRNA transcript which is present in all standard fusion partners derived from the original MOPC-21 tumor (including SP2/0). As a result of the aberrant mRNA, the invariant cysteine at position 23 is replaced by a tyrosine residue, and the VJ joint is out of frame, resulting in a stop codon at position 105.

[0059] It is common for lymphoid or hybridoma cells to synthesize more than one rearranged light immunoglobulin mRNA. These mRNAs are usually non productive due to the presence of termination codons or frame shifts not usually seen in functional V_K genes. These pseudo messengers often present major problems when cloning immunoglobulin genes from hybridomas because they are very good substrates for V region PCR, despite the fact that they do not encode functional polypeptides.

[0060] The 11-1F4 V_K gene sequence was identified after detailed sequence analysis of seven separate PCR clones, isolated from two different PCR products to yield SEQ. ID NO: 36. Since all sequences were identical, it

was accepted as the correct 11-1F4 kappa light chain variable region sequence.

[0061] The cloned V_H and V_K region genes were used to make the chimeric mouse-human 11-1F4 monoclonal antibody, which was then be analyzed to confirm specific binding to AL fibrils.

EXAMPLE 2

Construction of chimeric mouse-human 11-1F4 (c11-1F4) antibody

[0062] In order to allow transient expression of the 11-1F4 V_H and V_K variable region genes described above in mammalian cells as part of a chimeric mouse -human antibody, it was necessary to modify the 5'- and 3'-ends using specifically designed PCR primers (Table 5). The oligonucleotide primers F39836 and F39837 were used to PCR modify the 11-1F4 V_K gene, while primers F39835 and F58933 were used to PCR modify the 11-1F4 V_H gene. The back (BAK) primers F39836 and F39835 introduced a *Hind*III restriction site, a Kozak translation initiation site, and an immunoglobulin leader sequence to the 5' ends of the V_K and V_H genes respectively. The forward (FOR) oligonucleotide primer F39837 introduced a splice donor site and a *Bam*HI restriction site to the 3' end of the V_K gene while the forward (FOR) oligonucleotide primer F58933 appended the first 22 base pairs of the gamma-1CH_1 gene including an *Apa*I restriction site to the 3' end of the V_H gene.

Table 5. Oligonucleotide primers used to PCR modify the 11-1F4 heavy and kappa light chain variable region genes.

Name	Sequence 5' -> 3'	SEQ ID NO:
F39835 VH BAK	AAGCTTGCCGCCACCATGGCTGTCCTGGGGCTGCTCITC TGC	31
F58933 VH FOR	CCGATGGGCCCTTGGTGGAGGCTGAGGAGACGGTGACT GAGGTTCC	32
F39836 VK BAK	AAGCTTGCCGCCACCATGAAGTTGCCTGTTAGGCTGTTG GTGC	33
F39837 VK FOR	GGATCCACTCACGTTTGATTTCCAGCTTGGTCCCCCCTC CGA	34

[0063] The Kozak consensus sequence is crucial to the efficient translation of a variable region sequence (Kozak – *J Mol Bio* 196:947). It defines the correct AUG codon from which a ribosome commences translation, and the single most critical base is the adenine (or less preferably, a guanine) at position -3, upstream of the AUG start.

[0064] The immunoglobulin leader sequence ensures that the expressed antibody is secreted into the medium and therefore is easily harvested and purified. The leader sequences used in this instance were the murine 11-1F4 V_K and V_H leader sequences cloned from the hybridoma cDNA during the V_H and V_K cloning process.

[0065] The splice donor sequence is important for the correct in-frame attachment of the light chain variable region to its appropriate constant region, thus splicing out the 130 bp V_K:C_K intron. The heavy chain variable region was attached directly to its appropriate constant region gene via the *Apa*I site, thus eliminating the need for a splice donor site.

[0066] The sub-cloning restriction sites *Hind*III and *Bam*HI, and *Hind*III and *Apa*I, respectively, bracket the modified V_K and V_H variable region genes, while the use of different unique restriction sites ensured directional sub-cloning into the appropriate mammalian expression vector.

[0067] The 11-1F4 light chain variable region gene was first carefully analyzed to identify any unwanted splice donor sites, splice acceptor sites, and Kozak sequences (see Table 6). Both the heavy and light chain variable region genes were analyzed for the presence of any extra sub-cloning restriction sites which would later interfere with the subcloning and/or expression of functional whole antibody. None were found.

Table 6 Sequences important for the efficient expression of immunoglobulin genes in mammalian cells.

Name	Consensus DNA Sequences
Kozak translation initiation site	CCGCC**R**CC**AUGG**
Kappa light chain splice donor site	AC::**GT**RAG**T**
Heavy chain splice donor site	AG::**GT**RAGT
Immunoglobulin splice acceptor site	YYYYYYYYYYNC**AG**::G

Bases shown in bold are considered to be invariant within each consensus sequence.

[0068] Separate PCR reactions were prepared as follows, one for each variable region gene. The plasmids 11-1F4 V_H.pCR2.1 and 11-1F4 V_K.pCR2.1 described above were used as templates. A 100 µl reaction mixture was prepared in each PCR tube, each mixture containing up to 41µl of sterile water, 10 µl of 10 x PCR buffer I, 8 µl of the 10 mM stock solution of dNTPs, 1µl of 10 mM of 5' forward primer, 1µl of the 10 mM 3' Reverse primer, and 1µl of a 1/10 dilution of template DNA. Finally, 0.5 µl of AmpliTaq® DNA polymerase (2.5 units) was added before overlaying the completed reaction mixture with 50 µl of mineral oil. The reaction tubes were loaded into a DNA thermal cycler and cycled (after an initial melt at 94° C for 1 min) at 94° C for 30sec, 68° C for 30 sec and 72° C for 50 sec over 25 cycles. The completion of the last cycle was followed with a final extension step at 72° C for 7 min before cooling to 4° C. A 10 µl aliquot from each PCR reaction tube was run on a 1.2% (w/v) agarose/ 1 X TBE buffer gel containing 0.5 µg/ml ethidium bromide to determine size and presence of a PCR- product. Positive PCR-clones were about 420bp in size. Those putative positive PCR products so identified were directly cloned into the pCR2.1 vector, provided by the Topo TA Cloning® kit, and transformed into TOP10 competent cells as described in the manufacturer's protocol. Colonies containing the plasmid with a correctly sized insert were identified by PCR-

screening the colonies using the 1212 and 1233 oligonucleotide primers (Table 3) according to the method of Güssow and Clackson. Those putative positive clones so identified were double-stranded plasmid DNA sequenced using the ABI PRISM 310 Genetic Analyzer and the ABI PRISM BigDye™ terminator. Two positive clones each of the Topo TA cloned V_H and V_K genes were sequenced.

[0069] Clones containing the correctly modified 11-1F4 V_H and 11-1F4 V_K genes were identified and the modified V genes from these clones were subcloned into their respective expression vectors to facilitate the expression of chimeric heavy and kappa light chains in mammalian cells. The modified 11-1F4 V_K gene was subcloned into the expression vector pKN100 (Figure 4) as a *Hind*III-*Bam*HI fragment; this vector contains a human kappa constant region gene (allotype: Km (3 Ala153, Ser191)). The modified 11-1F4 V_H gene was also subcloned as a *Hind*III-*Apa*I fragment into the expression vector pG1D200 (Figure 5); this vector contained a human γ1 constant region gene (allotype: G1m (-1 Glu377, Met38I, -2 Ala462, 3 Arg222, Ser229)). Both the kappa and γ1 constant region allotypes used are commonly found in the caucasian population. The ligated expression constructs, 11-1F4VK.pKN100 and 11- 1F4VH.pG1D200, were then used to transform DH5α competent cells, and positive clones were identified using the PCR screening method discussed above with the original PCR modification primers (Table 4). The expression vectors are readily available.

EXAMPLE 3

Construction of a single supervector for transient expression of chimeric 11-1F4 in COS Cells.

[0070] A single supervector expressing both immunoglobulin chains of the chimeric 11-1F4 antibody was constructed as follows. The 11-1F4 kappa light chain expression cassette (which contained the HCMVi promoter, the 11-1F4 kappa light chain variable region gene, and the kappa light chain constant region gene) was restriction enzyme digested (EcoRI at positions 1 and 2490) out of the 11-1F4VK.pKN100 construct (Figure 4) and subsequently ligated into the 11-

1F4VHpG1D200 construct via the unique EcoRI (position 4297, Figure 5). This ligation resulted in the construction of a supervector construct, pG1KD200-11-1F4, containing both the heavy and kappa light chains of the 11-1F4 chimeric antibody.

EXAMPLE 4

Transient expression of the chimeric γ1/κ.11-IF4 whole antibody in COS cells

[0071] The chimeric 11-IF4 antibody was transiently expressed in COS cells from the European Collection of Cell Cultures (ECACC) in two ways:

(i) By cotransfection of 10μg of each of the vector constructs 11-1F4VK.pKN100 and 11-1F4VH.pG1D200. Co-transfections were carried out in duplicate.

(ii) By transfection of I3μg of the single supervector construct pG1KD200-11-1F4. Supervector transfections were carried out five times.

[0072] The following transfection method was used. The COS cell line was grown in DMEM supplemented with 10% (v/v) FCS, 580 μg/ml L-glutamine and 50 Units/ml penicillin/ 50 μg/ml streptomycin ("media") in a 150 cm^2 flask until confluent. The cells were trypsinized, spun down in a bench top centrifuge (250 g for 5 min), then re-suspended in 6 ml of media before dividing them equally between three 150 cm^2 flasks, each containing 25 ml of fresh, pre-warmed media. The cells were incubated overnight at 37 °C in 5% CO_z and then harvested the next day while they are still growing exponentially. Each flask contained approximately 1 x 10^7 cells. The cells were trypsinized again, pelleted as before, and washed in 20 ml of PBS, following which they were re-suspend in sufficient PBS to create a cell concentration of 1 x $I0^7$ cells/ml. 700 μl of these washed COS cells were pipetted into a Gene Pulser® cuvette, to which was then added 1 μl of both the heavy chain and kappa light chain expression vector DNA (each at 10 μg) or 13 μg of the super-vector construct. A 1900 Volt, 25 μFarad capacitance pulse was delivered to the mixture using the Bio-Rad Gene Pulser® apparatus. The pulsing was repeated for each experimental transfection

and a "no DNA" control (in which the COS cells were electroporated in the absence of any DNA). A positive control of a previously-expressed antibody was also carried out to test the efficiency of the COS cells.

[0073] The COS cells were allowed to recover at room temperature for 10 min, then gently pipetted the into a 10 cm diameter tissue culture dish containing 8 ml of pre- warmed DMEM supplemented with 10% (v/v) γ -globulin free FBS, 580 µg/ml L- glutamine and 50 Units/ml penicillin / 50 µg/ml streptomycin, and incubated in 5% CO_2 at 37° C for 72 hours before harvesting the COS cell supernatant for analysis. After incubation for 72 hours the medium was collected, spun to remove cell debris and analyzed by ELISA for chimeric antibody production and antigen binding of the c11-1F4 antibody.

EXAMPLE 5

Quantification of the chimeric γ1/κ 11-1F4 antibody via capture ELISA

[0074] Following expression, the whole IgG molecules present in the COS cell supernatant were quantified using a capture ELISA assay. IgG molecules were captured on a Nunc-Immuno MaxiSorb™ plate via an immobilized goat anti-human IgG, Fcγ fragment - specific antibody, and detected via an anti-human kappa light chain peroxidase conjugated antibody. A standard curve was generated by capturing and detecting known concentrations of a standard IgG antibody on the same plate in the same way as follows. Each well of a 96-well immunoplate was coated with 100 µl aliquots of 0.4 µg/ml goat anti-human IgG antibody diluted in PBS and incubated overnight at 4° C. The excess coating solution was removed and the plate was washed three times with 200 µl/well of washing buffer (1xPBS, 0.1% TWEEN). Into all wells except the wells in column 2, rows B to G, was dispensed 100µl of SEC buffer. A 1µg/ml solution of the human IgG1/kappa antibody in SEC buffer was prepared to serve as a standard and 200 µl/well was pipetted into the wells in column 2, rows B and C. The medium from the transfected cos cells was centrifuged (250g, 5 min), saving the supernatant. An aliquot of 200 µl of the supernatant from the "no DNA" control (in which COS cells were transfected in the absence of DNA) was

pipetted into the well in column 2, row D, and aliquots of 200 µl/well of experimental supernatants were pipetted into the wells in column 2, rows E, F, and G. The 200 µl aliquots in the wells of column 2, rows B to G were mixed and then 100 µl was transferred from each well to the neighboring well in column 3. This process was continued to column 11 with a series of 2-fold dilutions of the standard, control, and experimental samples, following which all were incubated at 37° C for 1 hour and all the wells were rinsed six times with 200 µl aliquots of washing buffer. The goat anti-human kappa light chain peroxidase conjugate was diluted 5000-fold in SEC buffer and 100 µl of the diluted conjugate added to each well, followed by a repetition of the incubation and rinsing steps. To each well was added 150µl of K-BLUE substrate, followed by incubation in the dark at 25° C for 10min. The reaction was stopped by adding 50 µl of RED STOP solution to each well and the optical density was read at 655nm.

EXAMPLE 6

Binding analysis of the chimeric 11-1F4 antibody

[0075] The chimeric 11-1F4 antibody was tested for binding to amyloid fibrils using a direct binding ELISA assay. Synthetic fibrils were formed from an immunoglobulin light chain protein and used to monitor the reactivity of the antibody in a solid-state ELISA-based assay using a "low- binding" polystyrene plates (Costar,# 3474). Immediately prior to coating the plate, a mass of 250 µg of fibrils was diluted to 1 ml with coating buffer (0.1% bovine serum albumin in phosphate buffered saline pH 7.5). The sample was then sonicated for 20 sec using a Tekmar Sonic Disruptor sonicating probe, with the power set to 40% of maximum, resulting in a solution of short fibrils composed of up to 2-5 protofiliments each. This solution was then diluted to 5 ml, mixed well by vortex, and aliquoted into the wells of the plate. This process yielded 50 µl of fibril solution having a concentration of 50 µg/ ml in each well. The plate was then dried overnight by placing it uncovered in a 37° C incubator.

[0076] The ELISA assay was then performed as follows within 48 hours of preparing the plate. The wells were blocked by the addition of 100 µl of I% BSA

in PBS and incubated for 1 hour at room temperature on a shaker. The plate was washed x3 in PBS, 0.05% Tween 20 (v/v). To each well of the plate was added 50 µl of a solution of c11-1F4 (3µg/ml antibody in 0.1% BSA/PBS) and the plate incubated at room temperature for 1 hour on a shaker. The plate was again washed x3 (as before) and detection of bound antibody was accomplished using a biotinylated goat anti-mouse IgG antibody (Sigma# B-8774, anti-heavy and light-chain).

Results

[0077] Sequence analysis of the successfully modified V_H and V_K genes revealed the correct sequence was present. Detailed DNA and amino acid sequences of the modified 11-1F4 V_K and V_H genes are presented in Figures 3 & 4. The modified V_K and V_H genes were successfully cloned into the mammalian expression vectors pG1D200 and pKN100 respectively, and the resulting 11-1F4VK.pKN100 and 11-1F4VHpG1D200 constructs were used for cotransfection of mammalian cells.

[0078] The 11-1F4VK.pKN100 and 11-1F4VHpG1D200 constructs were also subsequently used to construct a single supervector (pG1KD200-11-1F4), which expressed the chimeric 11- 1F4 antibody in mammalian cells. The chimeric ll-1F4 antibody expression levels, from both cotransfections and supervector transfections of ECACC COS cells were assayed. The expression levels observed from the pG1KD200-11-1F4 supervector transfections (10326 ng/ml) were 3.7 fold higher than the levels observed from the corresponding co-transfections of the 11-1F4VK.pKN100 and 11-1F4VHpG1D200 constructs (2820 ng/ml).

[0079] Following expression and quantification, the chimeric 11-1F4 antibody was tested for binding to target antigen (amyloid fibrils kindly supplied by the NCI) by direct binding ELISA. The results of the binding ELISA are presented in Figure 8. Supenatants from the two best individual pG1KD200-11-1F4 supervector transfections were assayed in parallel with one supernatant from the corresponding co-transfection.

[0080] The results indicated that the chimeric 11-1F4 antibody bound to the amyloid fibrils with a higher affinity than its murine equivalent. This result is surprising and unexpected because normally a chimeric antibody would be expected to have a binding affinity comparable to the original murine antibody. Without intending to be bound by the particular mechanism, the inventors believe it is possible that the net effect of combining the 11-1F4 murine V regions with the human γ1/κ C regions used to create the chimeric 11-1F4 antibody produced an antibody of higher affinity.

[0081] In the description and claims of this specification the word "comprise" and variations of that word, such as "comprises" and "comprising" are not intended to exclude other features, additives, components, integers or stepsbut rather, unless otherwise stated explicitly, the scope of these words should be construed broadly such that they have an inclusive meaning rather than an exclusive one.

[0082] Although the compositions and methods of the invention have been described in the present disclosure by way of illustrative examples, it is to be understood that the invention is not limited thereto and that variations can be made as known by those skilled in the art without departing from the teachings of the invention defined by the appended claims.

CLAIMS

What is claimed is:

1) A chimeric mouse-human antibody which comprises the V_K region of SEQ ID NO: 47 and the V_H region of SEQ ID NO: 48.

2) The chimeric mouse-human antibody of claim 1 which binds to an epitope expressed by the β-pleated sheet configuration of amyloid fibrils with higher affinity than the mouse antibody comprising the V_K region of SEQ ID NO: 36 and the V_H region of SEQ ID NO: 35.

3) A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

4) A method of treating an amyloid deposition disease in a human patient in need of such treatment which comprises administering to the patient the antibody of claim 1 together with a pharmaceutically acceptable carrier, in an amount effective to treat said amyloid deposition disease.

5) The method of claim 4 wherein the amyloid deposition disease is primary amyloidosis.

6) A method of producing a chimeric antibody which comprises co-transfection in mammalian cells of the vector constructs 11-1F4VK.pKN100 and 11-F4VH.pG1D200 or transfection in mammalian cells of the supervector construct pG1KD200-11-1F4.

7) The method of claim 6 wherein the co-transfection of the vector constructs 11-1F4VK.pKN100 and 11-F4VH.pG1D200 or transfection of a supervector construct pG1KD200-11-1F4 takes place in COS cells.

8) The method of claim 6 which comprises co-transfection of the vector constructs 11-1F4VK.pKN100 and 11-F4VH.pG1D200.

9) The method of claim 6 which comprises transfection of the supervector construct pG1KD200-11-1F4.

10) The method of claim 7 which comprises co-transfection of the vector constructs 11-1F4VK.pKN100 and 11-F4VH.pG1D200.

11) The method of claim 7 which comprises transfection of the supervector construct pG1KD200-11-1F4.

12) A vector construct selected from the group consisting of 11-1F4VK.pKN100, 11-1F4VHpG1D200, and pG1KD200-11-1F4.

13) The vector construct of claim 12 which is 11-1F4VK.pKN100.

14) The vector construct of claim 12 which is 11-1F4VHpG1D200.

15) The vector construct of claim 12 which is pG1KD200-11-1F4.

16) A method of detecting the presence of amyloid deposits in a patient suspected of having such deposits which comprises administering to the

patient an amount of the antibody of claim 1 having a detectable label attached thereto, the amount of antibody administered being sufficient to allow detection of amyloid deposits if such are present.

17) The method of claim 16 wherein the detectable label is ^{124}I.

18) A chimeric mouse-human antibody produced by the method of claim 6.

19) A chimeric mouse-human antibody produced by the method of claim 8.

20) A chimeric mouse-human antibody produced by the method of claim 9.

21) A polypeptide selected from SEQ. ID NO: 47 and SEQ. ID NO: 48.

22) A polynucleotide selected from SEQ. ID NO: 42 and SEQ ID NO: 45.

Figure 1


TWO 11-1F4 HYBRIDOMA (SP2/0) CLONES
B2C4
B2D6
The following procedure was undertaken separately for each of the hybridoma clones.
(a) 10^8 hybridoma cells harvested separately from each clone
(b) Total RNA isolated separately from cells of each clone
(c) 1st strand cDNA synthesis performed separately on RNA from each clone
mRNA
Not I-$(dt)_{18}$
one reaction
1st strand cDNA
(d) PCR amplification of the 11-1F4 heavy and light chain variable region genes (V_H and V_K) separately from cDNA from each clone
MHV1-12
1st strand cDNA
MHC1-3 (mix)
twelve reactions
Leader
V_H
C_H
MKV1-11
1st strand cDNA
MKC
eleven reactions
Leader
V_K
C_K

Figure 2


10
30
50
caggtgcagctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatc
gtccacgtcgacttcctcagtcctggaccggaccaccgcgggagtgtctcggacaggtag
Q V Q L K E S G P G L V A P S Q S L S I
70
90
110
-----CDR1------
acatgcactgtctcagggttctcattaagcagctatggtgtaagctgggttcgccagcct
tgtacgtgacagagtcccaagagtaattcgtcgataccacattcgacccaagcggtcgga
T C T V S G F S L S S Y G V S W V R Q P
130
150
170
ccaggaaagggtctggagtggctgggagtaatatggggtgacgggagcacaaattatcat
ggtcctttcccagacctcaccgaccctcattatacccccactgccctcgtgtttaatagta
P G K G L E W L G V I W G D G S T N Y H
190
210
230
------CDR2--------------------
ccaaatctcatgtccagactgagtatcagcaaggatatttccaagagccaagttctcttc
ggtttagagtacaggtctgactcatagtcgttcctataaaggttctcggttcaagagaag
P N L M S R L S I S K D I S K S Q V L F
250
270
290
--CDR3---
aaactgaatagtctgcaaactgatgacacagccacgtactactgtgtcaccttggactac
tttgacttatcagacgtttgactactgtgtcggtgcatgatgacacagtggaacctgatg
K L N S L Q T D D T A T Y Y C V T L D Y
310
330
tggggtcaaggaacctcagtcaccgtctcctca
accccagttccttggagtcagtggcagaggagt
W G Q G T S V T V S S

Figure 3


10
30
50
gatgttgtgatgacccaaactccactctccctgcctgtcagtcttggagatcaagcctcc
ctacaacactactgggtttgaggtgagagggacggacagtcagaacctctagttcggagg
D V V M T Q T P L S L P V S L G D Q A S
70
90
110
CDR1
atctcttgcagatctagtcagagccttgtacatagaaatggaaacacctatttacattgg
tagagaacgtctagatcagtctcggaacatgtatctttacctttgtggataaatgtaacc
I S C R S S Q S L V H R N G N T Y L H W
130
150
170
CDR2
tacctgcagaagccaggccagtctccaaagctcctgatctacaaagtttccaaccgattt
atggacgtcttcggtccggtcagaggtttcgaggactagatgtttcaaaggttggctaaa
Y L Q K P G Q S P K L L I Y K V S N R F
190
210
230
tctggggtcccagacaggttcagtggcagtggatcagggacagatttcacactcaagatc
agaccccagggtctgtccaagtcaccgtcacctagtccctgtctaaagtgtgagttctag
S G V P D R F S G S G S G T D F T L K I
250
270
290
CDR3
agcagagtggaggctgaggatttgggactttatttctgttttcaaactacatatgttccg
tcgtctcacctccgactcctaaaccctgaaataaagacaaaagtttgatgtatacaaggc
S R V E A E D L G L Y F C F Q T T Y V P
310
330
aacacgttcggaggggggaccaagctggaaataaaa
ttgtgcaagcctccccctggttcgacctttatttt
N T F G G G T K L E I K

Figure 4


EcoRI (1)
"Arnie"
HCMVi
promoter
HindIII
BamHI
pKN100
(7694 bp.)
neomycin resistance
gene
Human κ constant
region (cDNA)
BglII (5434)
"Arnie"
EcoRI (2490)
ampicillin resistance
gene
ColE1


"Arnie"
ampicillin resistance gene
Human γ-1 constant region (cDNA)
ApaI(5944)
HindIII (5880)
MCS
pG1D200
(7251bp)
HCMVi promoter
ColE1
dhfr-resistance gene
"Arnie"
EcoRI (4297)
BglII (3227)

Figure 5


5'-aagcttgccgccaccatgaagttgcctgttaggctgttggtgc-3'
HindIII Kozak
Leader
aagcttgccgccaccatgaagttgcctgttaggctgttggtgctgatgttctggattcctgcttccagcagt
ttcgaacggcggtggtacttcaacggacaatccgacaaccacgactacaagacctaaggacgaaggtcgtca
M K L P V R L L V L M F W I P A S S S
10 30 50
gatgttgtgatgacccaaactccactctccctgcctgtcagtcttggagatcaagcctcc
ctacaacactactgggtttgaggtgagagggacggacagtcagaacctctagttcggagg
D V V M T Q T P L S L P V S L G D Q A S
70 90 110
CDR1
atctcttgcagatctagtcagagccttgtacatagaaatggaaacacctatttacattgg
tagagaacgtctagatcagtctcggaacatgtatctttacctttgtggataaatgtaacc
I S C R S S Q S L V H R N G N T Y L H W
130 150 170
CDR2
tacctgcagaagccaggccagtctccaaagctcctgatctacaaagtttccaaccgattt
atggacgtcttcggtccggtcagaggtttcgaggactagatgtttcaaaggttggctaaa
Y L Q K P G Q S P K L L I Y K V S N R F
190 210 230
tctggggtcccagacaggttcagtggcagtggatcagggacagatttcacactcaagatc
agaccccagggtctgtccaagtcaccgtcacctagtccctgtctaaagtgtgagttctag
S G V P D R F S G S G S G T D F T L K I
250 270 290
CDR3
agcagagtggaggctgaggatttgggactttatttctgttttcaaactacatatgttccg
tcgtctcacctccgactcctaaaccctgaaataaagacaaaagtttgatgtatacaaggc
S R V E A E D L G L Y F C F Q T T Y V P
310 330
BamHI
aacacgttcggaggggggaccaagctggaaatcaaacgtgagtggatcc
ttgtgcaagcctccccctggttcgacctttagtttgcactcacctagg
N T F G G G T K L E I K
3'-agcctccccctggttcgacctttagtttgcactcacctagg-5'

Figure 6

Figure 7


5'-aagctttccgccaccatggctgtcctggggctgctcttctgc-3'
HindIII Kozak
Leader
aagcttgccgccaccatggctgtcctggggctgctcttctgcctggtgacattcccaagctgtgtcctgtcc
ttcgaacggcggtggtaccgacaggaccccgacgagaagacggaccactgtaagggttcgacacaggacagg
M A V L G L L F C L V T F P S C V L S
10 30 50
caggtgcagctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccat
gtccacgtcgacttcctcagtcctggaccggaccaccgcgggagtgtctcggacaggta
Q V Q L K E S G P G L V A P S Q S L S I
70 90 110
-----CDR1------
acatgcactgtctcagggttctcattaagcagctatggtgtaagctgggttcgccagcc
tgtacgtgacagagtcccaagagtaattcgtcgataccacattcgacccaagcggtcgg
T C T V S G F S L S S Y G V S W V R Q P
130 150 170
ccaggaaagggtctggagtggctgggagtaatatggggtgacgggagcacaaattatca
ggtcctttcccagacctcaccgacccatcattataccccactgccctcgtgtttaatagt
P G K G L E W L G V I W G D G S T N Y H
190 210 230
------CDR2----------
ccaaatctcatgtccagactgagtatcagcaaggatatttccaagagccaagttctctt
ggtttagagtacaggtctgactcatagtcgttcctataaaggttctcggttcaagagaa
P N L M S R L S I S K D I S K S Q V L F
250 270 290
--CDR3--
aaactgaatagtctgcaaactgatgacacagccacgtactactgtgtcaccttggacta
tttgacttatcagacgtttgactactgtgtcggtgcatgatgacacagtggaacctgat
K L N S L Q T D D T A T Y Y C V T L D Y
310 330
----------CH1---------->
tggggtcaaggaacctcagtcaccgtctcctcagcctccaccaagggcccatcgg
accccagttccttggagtcagtggcagaggagtcggaggtggttcccgggtagcc
W G Q G T S V T V S S
ApaI
3'-ccttggagtcagtggcagaggagtcggaggtggttcccgggtagcc-5'


1.5
1.25
1
0.75
0.5
0.25
0
ABSORBANCE 405nm
0.001
0.01
0.1
1
10
100
antibody conc. (ug/ml)
murine 11-1F4
new sv (i)
new sv (ii)
new co-transfection

FIG. 8

SEQUENCE LISTING

<110> Trustees of Columbia University in the City of New York

<120> CHIMERIC ANTIBODIES FOR TREATMENT OF AMYLOID DEPOSITION DISEASES

<130> 8441-0004WO

<150> US 62/526835
<151> 2017-06-29

<160> 48

<170> PatentIn version 3.5

<210> 1
<211> 31
<212> DNA
<213> Mus musculus

<400> 1
atgaagattg cctgttaggc tgttggtgct g 31

<210> 2
<211> 31
<212> DNA
<213> Mus musculus

<400> 2
atggagwcag acacactccc tgytatgggt g 31

<210> 3
<211> 30
<212> DNA
<213> Mus musculus

<400> 3
atgagtgtgc tcactcaggt cctggsgttg 30

<210> 4
<211> 33
<212> DNA
<213> Mus musculus

<400> 4
atgaggrccc ctgctcagwt tyttggmwtc ttg 33

<210> 5

<211> 30
<212> DNA
<213> Mus musculus

<400> 5
atggatttwc aggtgcagat twtcagcttc 30

<210> 6
<211> 29
<212> DNA
<213> mus musculus

<400> 6
atgaggtkcy ytgytsayct yctctgrgg 29

<210> 7
<211> 32
<212> DNA
<213> Mus musculus

<400> 7
atgggcwtca aagatggagt cacakwyycw gg 32

<210> 8
<211> 31
<212> DNA
<213> Mus musculus

<400> 8
atgtggggay ctkttttycm mtttttcaat g 31

<210> 9
<211> 25
<212> DNA
<213> Mus musculus

<400> 9
atggtrtccw casctcagtt ccttg 25

<210> 10
<211> 27
<212> DNA
<213> Mus musculus

<400> 10
atgtatatat gtttgttgtc tatttct 27

<210> 11
<211> 28
<212> DNA
<213> Mus musculus

<400> 11
atggaagccc cagctcagct tctcttcc 28

<210> 12
<211> 20
<212> DNA
<213> Mus musculus

<400> 12
actggatggt gggaagatgg 20

<210> 13
<211> 27
<212> DNA
<213> Mus musculus

<400> 13
atgaaatgca gctggggcat sttcttc 27

<210> 14
<211> 26
<212> DNA
<213> Mus musculus

<400> 14
atgggatgga gctrtatcat sytctt 26

<210> 15
<211> 27
<212> DNA
<213> Mus musculus

<400> 15
atgaagwtgt ggttaaactg ggttttt 27

<210> 16
<211> 25
<212> DNA
<213> Mus musculus

<400> 16

atgractttg ggytcagctt grttt 25

<210> 17
<211> 32
<212> DNA
<213> Mus musculus

<400> 17
atgggactcc aggcttcaat ttagttttcc tt 32

<210> 18
<211> 29
<212> DNA
<213> Mus musculus

<400> 18
atggcttgtc yttrgsgctr ctcttctgc 29

<210> 19
<211> 27
<212> DNA
<213> Mus musculus

<400> 19
atggratgga gckggrgtct ttmtctt 27

<210> 20
<211> 23
<212> DNA
<213> Mus musculus

<400> 20
atgagagtgc tgattctttt gtc 23

<210> 21
<211> 31
<212> DNA
<213> Mus musculus

<400> 21
atggmttggg tgtggamctt gcttattcct g 31

<210> 22
<211> 28
<212> DNA
<213> Mus musculus

<400> 22
atgggcagac ttaccattct cattcctg 28

<210> 23
<211> 28
<212> DNA
<213> Mus musculus

<400> 23
atggattttg ggctgatttt ttttattg 28

<210> 24
<211> 27
<212> DNA
<213> Mus musculus

<400> 24
atgatggtgt taagtcttct gtacctg 27

<210> 25
<211> 21
<212> DNA
<213> Mus musculus

<400> 25
cagtggatag acagatgggg g 21

<210> 26
<211> 21
<212> DNA
<213> Mus musculus

<400> 26
cagtggatag accgatgggg g 21

<210> 27
<211> 21
<212> DNA
<213> Mus musculus

<400> 27
cagtggatga gctgatgggg g 21

<210> 28
<211> 21

<212> DNA
<213> Mus musculus

<400> 28
caagggatag acagatgggg c 21

<210> 29
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> The sequence contains sequences from Homo sapiens and Mus musculus

<400> 29
gttttcccag tcacgac 17

<210> 30
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> The sequence contains sequences from Homo sapiens and Mus musculus

<400> 30
agcggataat ttcacacagg a 21

<210> 31
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> The sequence contains sequences from Homo sapiens and Mus musculus

<400> 31
aagcttgccg ccaccatggc tgtcctgggg ctgctcttct gc 42

<210> 32
<211> 46
<212> DNA
<213> Artificial Sequence

<220>

<223> The sequence contains sequences from Homo sapiens and Mus musculus

<400> 32
ccgatgggcc cttggtggag gctgaggaga cggtgactga ggttcc 46

<210> 33
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> The sequence contains sequences from Homo sapiens and Mus musculus

<400> 33
aagcttgccg ccaccatgaa gttgcctgtt aggctgttgg tgc 43

<210> 34
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> The sequence contains sequences from Homo sapiens and Mus musculus

<400> 34
ggatccactc acgtttgatt tccagcttgg tccccctcc ga 42

<210> 35
<211> 111
<212> PRT
<213> Mus musculus

<400> 35

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
1 5 10 15

Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr
20 25 30

Gly Val Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45

```
Gly Val Ile Trp Gly Asp Gly Ser Thr Asn Tyr Lys Pro Asn Leu Met
    50                  55                  60


Ser Arg Leu Ser Ile Ser Lys Asp Ile Ser Lys Ser Gln Val Leu Phe
65                  70                  75                  80


Lys Leu Asn Ser Leu Gln Thr Asp Asp Thr Ala Thr Tyr Tyr Cys Val
                85                  90                  95


Thr Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
            100                 105                 110


<210>  36
<211>  112
<212>  PRT
<213>  Mus musculus

<400>  36

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1               5                   10                  15


Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Arg
            20                  25                  30


Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
        35                  40                  45


Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
    50                  55                  60


Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80


Ser Arg Val Glu Ala Glu Asp Leu Gly Leu Tyr Phe Cys Phe Gln Thr
                85                  90                  95


Thr Tyr Val Pro Asn Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110


<210>  37
```

<211> 131
<212> PRT
<213> Artificial Sequence

<220>
<223> The sequence contains sequences from Homo sapiens and Mus musculus

<400> 37

Met Lys Leu Pro Val Arg Leu Leu Val Leu Met Phe Trp Ile Pro Ala
1 5 10 15

Ser Ser Ser Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val
20 25 30

Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu
35 40 45

Val His Arg Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro
50 55 60

Gly Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
65 70 75 80

Gly Val Pro Arg Asp Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
85 90 95

Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Leu Tyr Phe Cys
100 105 110

Phe Gln Thr Thr Tyr Val Pro Asn Thr Phe Gly Gly Gly Thr Lys Leu
115 120 125

Glu Ile Lys
130

<210> 38
<211> 130
<212> PRT
<213> Artificial Sequence

<220>

<223> The sequence contains sequences from Homo sapiens and Mus musculus

<400> 38

```
Met Ala Val Leu Gly Leu Leu Phe Cys Leu Val Thr Phe Pro Ser Cys
1               5                  10                  15

Val Leu Ser Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala
            20                  25                  30

Pro Ser Gln Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu
        35                  40                  45

Ser Ser Tyr Gly Val Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu
    50                  55                  60

Glu Trp Leu Gly Val Ile Trp Gly Asp Gly Ser Thr Asn Tyr His Pro
65                  70                  75                  80

Asn Leu Met Ser Arg Leu Ser Ile Ser Lys Asp Ile Ser Lys Ser Gln
                85                  90                  95

Val Leu Phe Lys Leu Asn Ser Leu Gln Thr Asp Asp Thr Ala Thr Tyr
            100                 105                 110

Tyr Cys Val Thr Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val
        115                 120                 125

Ser Ser
    130
```

<210> 39
<211> 333
<212> DNA
<213> Mus musculus

<400> 39

caggtgcagc tgaaggagtc aggacctggc ctggtggcgc cctcacagag cctgtccatc 60

acatgcactg tctcagggtt ctcattaagc agctatggtg taagctgggt tcgccagcct 120

ccaggaaagg gtctggagtg gctgggagta atatggggtg acgggagcac aaattatcat 180

ccaaatctca tgtccagact gagtatcagc aaggatattt ccaagagcca agttctcttc 240

aaactgaata gtctgcaaac tgatgacaca gccacgtact actgtgtcac cttcgactac 300

tggggtcaag gaacctcagt caccgtctcc tca 333

<210> 40
<211> 336
<212> DNA
<213> Mus musculus

<400> 40
gatgttgtga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60

atctcttgca gatctagtca gagccttgta catagaaatg gaaacaccta tttacattgg 120

tacctgcaga agccaggcca gtctccaaag ctcctgatct acaaagtttc caaccgattt 180

tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaagatc 240

agcagagtgg aggctgagga tttgggactt tatttctgtt ttcaaactac atatgttccg 300

aacacgttcg gaggggggac caagctggaa ataaaa 336

<210> 41
<211> 43
<212> DNA
<213> Mus musculus

<400> 41
aagcttgccg ccaccatgaa gttgcctgtt aggctgttgg tgc 43

<210> 42
<211> 422
<212> DNA
<213> Artificial Sequence

<220>
<223> The sequence contains sequences from Homo sapiens and Mus musculus

<400> 42
aagcttgccg ccaccatgaa gttgcctgtt aggctgttgg tgctgatgtt ctggattcct 60

gcttccagca gtgatgttgt gatgacccaa actccactct ccctgcctgt cagtcttgga 120

gatcaagcct ccatctcttg cagatctagt cagagccttg tacatagaaa tggaaacacc 180

tatttacatt ggtacctgca gaagccaggc cagtctccaa agctcctgat ctacaaagtt 240

tccaaccgat tttctggggt cccagacagg ttcagtggca gtggatcagg gacagatttc 300

acactcaaga tcagcagagt ggaggctgag gatttgggac tttatttctg ttttcaagac 360

tacatatgtt ccgaacacgt tcggaggggg gaccaagctg gaaatcaaac gtgagtggat 420

cc 422

<210> 43
<211> 42
<212> DNA
<213> Mus musculus

<400> 43
ggatccactc acgtttgatt tccagcttgg tccccctcc ga 42

<210> 44
<211> 42
<212> DNA
<213> Mus musculus

<400> 44
aagctttccg ccaccatggc tgtcctgggg ctgctcttct gc 42

<210> 45
<211> 426
<212> DNA
<213> Artificial Sequence

<220>
<223> The sequence contains sequences from Homo sapiens and Mus musculus

<400> 45
aagctttccg ccaccatggc tgtccctggg gctgctcttc tgcctggtga cattaccaag 60

ctgtgtcctg tcccaggtgc agctgaagga gtcaggacct ggcctggtgg agcctcacag 120

agcctgtcca tcacatgcac tgtctcaggg ttctcattaa gcagctatgg tgtaagctgg 180

gttcgccagc ccaggaaagg gtctggagtg gctgggagta atatggggtg acgggagcac 240

aaattatcat ccaaatctca tgtccagact gagtatcagc aaggatattt ccaagagcaa 300

gttctcttca aactgaatag tctgcaaact gatgacacag ccacgtacta ctgtgtcacc 360

ttggactact ggggtcaaag gaacctccag tcaccgtctc ctcagcctcc accacgggcc 420

catcgg 426

<210> 46
<211> 46
<212> DNA
<213> Mus musculus

<400> 46
ccgatgggcc cttggtggag gctgaggaga cggtgactga ggttcc 46

<210> 47
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> The sequence contains sequences from Homo sapiens and Mus musculus

<400> 47

Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly
1 5 10 15

Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Arg
20 25 30

Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60

Arg Asp Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Leu Gly Leu Tyr Phe Cys Phe Gln Thr
85 90 95

Thr Tyr Val Pro Asn Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 48
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> The sequence contains sequences from Homo sapiens and Mus musculus

<400> 48

Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
1 5 10 15

Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Ser Tyr
20 25 30

Gly Val Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45

Gly Val Ile Trp Gly Asp Gly Ser Thr Asn Tyr His Pro Asn Leu Met
50 55 60

Ser Arg Leu Ser Ile Ser Lys Asp Ile Ser Lys Ser Gln Val Leu Phe
65 70 75 80

Lys Leu Asn Ser Leu Gln Thr Asp Asp Thr Ala Thr Tyr Tyr Cys Val
85 90 95

Thr Leu Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
100 105 110